BZ-371 is under clinical development by Biozeus Pharmaceutical and currently in Phase I for Erectile Dysfunction. According to GlobalData, Phase I drugs for Erectile Dysfunction have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BZ-371’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BZ-371 is under development for the treatment of erectile dysfunction,non-arteritic anterior ischemic optic neuropathy, psoriasis, pulmonary arterial hypertension, atopic dermatitis, molluscum contagiosum, acne, glaucoma and acute respiratory distress syndrome. The drug candidate is formulated as a gel for the topical route of administration and also it is administered through inhalational route.
Biozeus Pharmaceutical overview
Biozeus Pharmaceutical (Biozeus) operates as a drug development company that develops new drugs to improve and save patients life. The company undertakes projects in an advanced stage of development with outstanding potential to become reference medicines for type I and II diabetes, obesity, erectile dysfunction and rheumatoid arthritis. It provides commercially viable, clinical-stage therapeutic opportunities for pharmaceutical and biotechnology company partners for completion of clinical trials, regulatory licensing and worldwide marketing and sales. The company’s pipeline of development projects includes various therapeutic areas such as oncology and inflammatory, metabolic, nervous system and other diseases. Biozeus is headquartered in Rio de Janeiro, Brazil.
For a complete picture of BZ-371’s drug-specific PTSR and LoA scores, buy the report here.